Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice
Kolar M, Lukas M, Malickova K, Prochazkova L, Bortlik M, Duricova D, Hruba V, Machkova N, Mitrova K, Vasatko M, Lukas M: Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 – results from clinical practice. Gastroenterologie a Hepatologie 2020, 74(1):28-34
Další publikace
A Novel Porcine Model of Crohn’s Disease Anastomotic Stricture Suitable for Evaluation and Training of Advanced Endoscopic
Techniques
přejít na článek
Techniques
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational
cohort
přejít na článek
cohort
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide
cohort
přejít na článek
cohort
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases
Centre
přejít na článek
Centre
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective
observation
přejít na článek
observation
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative
Colitis
přejít na článek
Colitis
Telemedicine and inflammatory bowel disease – results of the IBD Assistant pilot
project
přejít na článek
project
Biosimilars: concept, current status, and future perspectives in inflammatory bowel
diseases
přejít na článek
diseases
POCT system for the fecal calprotectin detection in the telemonitoring of patients with inflammatory bowel
disease
přejít na článek
disease
Early vedolizumab trough levels are not associated with short-term response in patients with inflammatory bowel
disease
přejít na článek
disease
Vedolizumab vs. ustekinumab as second-line therapy in Crohn’s disease in clinical
practice
přejít na článek
practice
The efficacy and safety of budesonide MMX (Cortiment®) for long-term maintenance therapy of ulcerative
colitis
přejít na článek
colitis
Budesonide MMX (Cortiment® 9 mg) in the treatment of ulcerative colitis in real clinical
practice
přejít na článek
practice
Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD
clinics
přejít na článek
clinics
Evaluation of Infliximab Therapy in Children with Crohn’s Disease Using Trough Levels
Predictors
přejít na článek
Predictors
The role of steroid hormones in the development of intrahepatic cholestasis of
pregnancy
přejít na článek
pregnancy